Summary

Overview
Global Intravenous Anticoagulants Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
A class of drugs known as intravenous (IV) anticoagulants is given directly into the bloodstream through IV infusion in order to treat or prevent irregular blood coagulation. Interfering with the blood coagulation cascade, a complicated sequence of events that eventually results in the formation of blood clots, is the main objective of intravenous anticoagulants. Thromboembolic events can be prevented or delayed by these anticoagulants, which work by blocking particular clotting factors or coagulation-related enzymes.
Intravenous anticoagulants have a crucial role in the prevention and treatment of disorders such deep vein thrombosis (DVT), pulmonary embolism (PE), and systemic embolism that are linked to aberrant blood clot formation. Intravenous anticoagulants can be quickly given in emergency scenarios, such as major pulmonary embolism or ischemic stroke, to stop further clot propagation and enhance patient outcomes.
Market Dynamics: Drivers and Restraints
Increasing the prevalence of venous thromboembolism
Venous thromboembolism (VTE) contributes significantly to the demand for intravenous anticoagulants, driving market growth. VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially life-threatening condition. The high incidence of VTE worldwide contributes to a substantial patient population requiring anticoagulant therapy.
Awareness about the risks and consequences of VTE has grown, leading to improved diagnostic capabilities and increased detection of VTE cases. As more cases are identified, the demand for anticoagulant treatment, particularly intravenous options, rises. VTE often occurs in hospitalized patients, especially those with reduced mobility, postoperative patients, or those with medical conditions predisposing them to clot formation.
In acute care settings, intravenous anticoagulants are commonly administered for rapid and effective anticoagulation. Intravenous anticoagulants are commonly used for the initial treatment of acute VTE episodes, especially in situations where rapid and potent anticoagulation is required. This includes cases of massive PE or extensive DVT. Thus rise of the diseases helps accelerates the market growth.
For instance, according to National Heart, Lung and Blood Institue (NIH), estimated that, deep vein thrombosis can also occur in the arms, especially if there is a large intravenous central line in the vein. Pulmonary embolism occurs when a clot breaks loose and travels through the bloodstream to the lungs. VTE is common. As many as 600,000 VTE cases occur each year in the United States. Thus above factors helps to drives the market growth.
Market Dynamics: Restraint
The high cost of intravenous anticoagulants drugs
The high cost of intravenous anticoagulants may limit access to these medications, particularly for patients who do not have adequate insurance coverage or financial resources. This can result in disparities in healthcare, with certain patient populations facing challenges in affording essential anticoagulant therapy.
Healthcare institutions, including hospitals and clinics, often operate within budget constraints. The high cost of intravenous anticoagulants may strain healthcare budgets, leading to restrictions on the volume of these medications that can be purchased and used within a healthcare system. High medication costs can affect patient adherence to prescribed treatment plans. Patients may be less likely to adhere to therapy if they face financial challenges in obtaining and continuing the use of intravenous anticoagulants. Thus cost of drugs decline the market growth.
For instance, the cost for argatroban intravenous solution (1 mg/mL) is around $112 for a supply of 50 milliliters. High development and manufacturing costs for anticoagulant drugs may act as a barrier to entry for new market players and innovative therapies. This can limit competition and hinder the development of more cost-effective options.
Segment Analysis
The global intravenous anticoagulants market is segmented based on type, application, end-user and region.
The Factor Xa inhibitor segment from the type segment accounted for approximately 39.7% of intravenous anticoagulants type share
Factor Xa inhibitors are a class of intravenous anticoagulant medications that target and inhibit the activity of factor Xa, a key enzyme in the coagulation cascade. These drugs interfere with the formation of blood clots by inhibiting factor Xa, which plays a central role in the conversion of prothrombin to thrombin. Factor Xa inhibitors are used for various medical conditions that require anticoagulation. For example, rivaroxaban directly inhibits factor Xa, preventing the conversion of prothrombin to thrombin and edoxaban inhibits factor Xa, similar to rivaroxaban and apixaban.
There is a growing market demand for safer and more convenient intravenous anticoagulant therapies, especially as the global population ages. The prevalence of conditions such as atrial fibrillation and venous thromboembolism has increased, creating a substantial patient population that could benefit from Factor Xa inhibitors. Thus due to the demand the companies follow teh strategies like product launches and others which helps to boost the segment growth.
For instance, in December 2021, Janssen Pharmaceutical Companies of Johnson & Johnson had approved two pediatric indications for XARELTO (rivaroxaban) and thromboprophylaxis (prevention of blood clots and blood-clot related events). In 2021, Janssen's development partner, Bayer, received approval for XARELTO in Canada, the European Union, the United Kingdom, Japan, Switzerland and in various Latin American countries for the treatment of VTE and prevention of VTE recurrence in the pediatric population.
Additionally, in December 2020, Natco Pharma had launched Rivaroxaban molecule, under brand RPIGAT. Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots. Rivaroxaban is currently sold by Bayer under brand name of Xarelto, in the Indian market. Thus above factors helps to boost the segment growth.
Geographical Analysis
North America accounted for approximately 42.4% of the market share in 2022
The increased demand for novel products and the rising incidence of cardiovascular diseases in this area are likely to lead North America to a significant market position in the global intravenous anticoagulants market. For instance, according to the CDC, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States.
One person dies every 33 seconds in the United States from cardiovascular disease. About 695,000 people in the United States died from heart disease in 2021—that’s 1 in every 5 deaths. In addition, according to American Heart Association, estimated that in 2020 in the United States, coronary heart disease (CHD) was the leading cause (41.2%) of deaths attributable to CVD in the United States, followed by stroke (17.3%), other CVD (16.8%), high blood pressure (12.9%), heart failure (9.2%), diseases of the arteries (2.6%).
Moreover, the existence of leading pharmaceutical and biotech companies involved with therapeutic development, along with a well-developed healthcare infrastructure, is significantly contributing to the expansion of the regional market. For instance, in June 2020, Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, had launched the APO-Apixaban tablets, Canada's first generic alternative to Eliquis. The market for anticoagulants is thus boosted in North America by the aforementioned factors, including the rise in chronic illnesses and the product launches by key players.
COVID-19 Impact Analysis
Since research on COVID-19 infection is moving quickly, the anticoagulant sector is projected to be significantly impacted. According to a study published in the American Journal of Cardiovascular Drugs in 2020, more than ten clinical trials are currently being conducted to evaluate the potential of anticoagulants in COVID-19 patients. Additionally, research is being conducted on parenteral administration strategies for these drugs for use in critically ill COVID-19 patients.
Therefore, it is anticipated that the COVID-19 pandemic will affect the relevant market directly as well as indirectly. Furthermore, the World Health Organization stated in a January 2021 Update that individuals with COVID-19, whether positive or suspected, have to have access to low-dose anticoagulants for follow-up treatment. Anticoagulants became more in demand as a result of COVID-19.
Market Segmentation
By Type
• Heparins
• Direct Thrombin Inhibitors
• Factor Xa Inhibitors
• Others
By Application
• Heart attack
• Deep vein thrombosis
• Pulmonary embolism
By End-User
• Hospitals
• Specialty Clinics
• Laboratories
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Pfizer, Inc, Sanofi, Fresenius Kabi AG, Baxter International, Bayer Inc, GlaxoSmithKline Inc, Mitsubishi Tanabe Pharma, Bristol-Myers Squibb Company, Novartis AG, Boehringer Ingelheim among others.
Why Purchase the Report?
• To visualize the global intravenous anticoagulants market segmentation based on type, application, end-user and region as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of intravenous anticoagulants market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global intravenous anticoagulants market report would provide approximately 69 tables, 58 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing the prevalence of venous thromboembolism
4.1.1.2. Rising the aging population
4.2. Restraints
4.2.1.1. The high cost of intravenous anticoagulants drugs
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Heparins *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Direct Thrombin Inhibitors
7.4. Factor Xa Inhibitors
7.5. Others
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Heart attack *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Deep vein thrombosis
8.4. Pulmonary embolism
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty Clinics
9.4. Laboratories
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Pfizer, Inc *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Sanofi
12.3. Fresenius Kabi AG
12.4. Baxter International
12.5. Bayer Inc
12.6. GlaxoSmithKline Inc
12.7. Mitsubishi Tanabe Pharma
12.8. Bristol-Myers Squibb Company
12.9. Novartis AG
12.10. Boehringer Ingelheim
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us